Skip to main content

Reducing animal experimentation in drug testing by human cardiomyocyte in vitro models derived from embryonic stem cells

Objective

The objective of the proposal is to establish stable cell lines that reliably reflect human cardiomyocyte properties by the development of models derived from human embryonic stem cells.

The aim is to deliver reliable in vitro models that could be used by the pharmaceutical industry to replace experimental animals in:
- investigations on pharmacological toxicity and safety of compounds in the drug discovery and development processes, and
- the testing of toxic effects of chemicals according to the new system of the Community on the Registration, Evaluation and Authorisation of Chemicals (REACH).

In the pharmaceutical industry reliable in vitro cell models would contribute to replace current techniques with animal experimentation in the selection and optimisation of lead compounds and in documentation of a selected drug candidate before it enters clinical phases. In the toxicity testing of chemical substances replacement of animal testing methods can be attained as well.

Call for proposal

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

LINKÖPING UNIVERSITY
Address

Linköping
Sweden

Participants (8)

CELLARTIS AB
Sweden
Address
Arvid Wallgrens Backe 20
Göteborg
EUROPEAN COMMISSION, DG JRC (JOINT RESEARCH CENTRE)
Belgium
Address
Rue De La Loi 200
Brussels
GÖTEBORGS UNIVERSITET
Sweden
Address
Vasaparken
Göteborg
H. LUNDBECK A/S
Denmark
Address
Ottiliavej 9
Valby
MULTI CHANNEL SYSTEMS MCS GMBH
Germany
Address
Aspenhaustrasse 21
Reutlingen
PHARMACELSUS GMBH
Germany
Address
Science Park 2
Saarbrücken
PRESENS PRECISION SENSING GMBH
Germany
Address
Josef Engert Strasse 11
Regensburg
UNIVERSITÄT DES SAARLANDES
Germany
Address

Saarbrücken